香港CK Life Sciences新子公司Sequencio Therapeutics正在推进约20个癌症疫苗项目，并计划明年在中国开展研究者发起试验，以加速人体试验进程。 CK Life Sciences副总裁兼首席科学官Melvin Toh Kean-meng博士表示，中国路径比传统监管流程更快，后者通常需一年半至两年才能给首位患者用药。
Sequencio Therapeutics是CK Life Sciences在香港新成立的子公司，该公司正推进约20个癌症疫苗项目。李嘉诚旗下的CK Life Sciences希望通过中国路径加速进入人体试验阶段。
“我们计划明年开展研究者发起试验[IITs]”，CK Life Sciences副总裁兼首席科学官Melvin Toh Kean-meng博士在最近一次采访中表示。
在中国，IITs允许制药公司比传统监管流程更快生成人体临床数据，后者通常需要一年半至两年才能给首位患者用药，Toh博士说。
“越早进入并越快获批，你的药物就能越快产生收入，”他表示。“第一个上市总有优势。”
由 AI 报道 AI 生成的图像 事实核查
Researchers at McGill University report a drug-based method to temporarily enhance natural killer (NK) cells—an immune cell type—by inhibiting two proteins, improving the cells’ ability to attack several aggressive cancers in preclinical experiments.
Venture capitalist Nisa Leung says mainland China and Hong Kong should ease listing rules for biotechnology companies and lower takeover thresholds for listed firms to capitalize on renewed foreign interest in the healthcare sector. She made the comments in a sideline interview during China's annual meetings of the CPPCC and NPC.
由 AI 报道
A Chinese research team has developed an AI platform called GalaxyVS that screens potential drugs in seconds.
Spain's National Cancer Research Centre (CNIO) is reviewing whether scientist Mariano Barbacid violated its code of good practices by failing to disclose a conflict of interest in an article retracted by the US National Academy of Sciences. The paper, on a pancreatic cancer therapy tested in mice, was withdrawn because the authors did not declare their shares in Vega Oncotargets, the company set to commercialize the patent. Despite knowing since March, Barbacid did not inform the Cris Cancer Foundation, which raised 3.6 million euros in donations.